ABVC 바이오파머 (ABVC) 주가

ABVC 바이오파머(ABVC)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.16 (+0.87%), 시가총액 $26.15M, 52주 범위 $0.91 ~ $4.74.

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

핵심 지표

• 현재가: $1.16 (+0.87%)
• 시가총액: $26.15M
• 52주 최저~최고: $0.91 ~ $4.74
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

ABVC 바이오파머의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

ABVC 바이오파머 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 보유 (3.0 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.50
• 순이익률: 0.00%
• 영업이익률: 375.82%

자주 묻는 질문